JP2007068723A - Antibacterial method using adhesive antibacterial sheet - Google Patents
Antibacterial method using adhesive antibacterial sheet Download PDFInfo
- Publication number
- JP2007068723A JP2007068723A JP2005258070A JP2005258070A JP2007068723A JP 2007068723 A JP2007068723 A JP 2007068723A JP 2005258070 A JP2005258070 A JP 2005258070A JP 2005258070 A JP2005258070 A JP 2005258070A JP 2007068723 A JP2007068723 A JP 2007068723A
- Authority
- JP
- Japan
- Prior art keywords
- antibacterial
- sheet
- adhesive
- volatile
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 110
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 78
- 239000000853 adhesive Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 46
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims description 30
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 28
- 239000012790 adhesive layer Substances 0.000 claims description 15
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims description 15
- 229930007845 β-thujaplicin Natural products 0.000 claims description 15
- 239000010410 layer Substances 0.000 claims description 13
- 230000035699 permeability Effects 0.000 claims description 10
- 239000006096 absorbing agent Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 abstract description 13
- 238000002347 injection Methods 0.000 abstract description 11
- 239000007924 injection Substances 0.000 abstract description 11
- 239000000243 solution Substances 0.000 abstract description 4
- -1 silver and copper Chemical compound 0.000 description 35
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 33
- 229920000858 Cyclodextrin Polymers 0.000 description 30
- 239000002985 plastic film Substances 0.000 description 16
- 239000000178 monomer Substances 0.000 description 15
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 239000004814 polyurethane Substances 0.000 description 9
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940048053 acrylate Drugs 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 6
- 239000005022 packaging material Substances 0.000 description 6
- 229920002635 polyurethane Polymers 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004721 Polyphenylene oxide Substances 0.000 description 4
- 229920006243 acrylic copolymer Polymers 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229940114077 acrylic acid Drugs 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010030 laminating Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 2
- VHBFEIBMZHEWSX-UHFFFAOYSA-N 2-isothiocyanatopropane Chemical compound CC(C)N=C=S VHBFEIBMZHEWSX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- LIMQQADUEULBSO-UHFFFAOYSA-N butyl isothiocyanate Chemical compound CCCCN=C=S LIMQQADUEULBSO-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229920006147 copolyamide elastomer Polymers 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920006122 polyamide resin Polymers 0.000 description 2
- 229920001225 polyester resin Polymers 0.000 description 2
- 239000004645 polyester resin Substances 0.000 description 2
- 229920005672 polyolefin resin Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920001567 vinyl ester resin Polymers 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- OUPZKGBUJRBPGC-UHFFFAOYSA-N 1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(CC2OC2)C(=O)N(CC2OC2)C(=O)N1CC1CO1 OUPZKGBUJRBPGC-UHFFFAOYSA-N 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- SDXHBDVTZNMBEW-UHFFFAOYSA-N 1-ethoxy-2-(2-hydroxyethoxy)ethanol Chemical compound CCOC(O)COCCO SDXHBDVTZNMBEW-UHFFFAOYSA-N 0.000 description 1
- JATNWMBUDXLMEO-UHFFFAOYSA-N 1-isothiocyanato-3-methylbutane Chemical compound CC(C)CCN=C=S JATNWMBUDXLMEO-UHFFFAOYSA-N 0.000 description 1
- KKASGUHLXWAKEZ-UHFFFAOYSA-N 1-isothiocyanatopropane Chemical compound CCCN=C=S KKASGUHLXWAKEZ-UHFFFAOYSA-N 0.000 description 1
- PHTZMGCAFZLFOL-UHFFFAOYSA-N 14-methylpentadecyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCCCCCCCCCCCCCC(C)C PHTZMGCAFZLFOL-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- OATHWIHWTWDNLJ-UHFFFAOYSA-N 2-(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCCCCCC(C)C OATHWIHWTWDNLJ-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 description 1
- MZNSQRLUUXWLSB-UHFFFAOYSA-N 2-ethenyl-1h-pyrrole Chemical compound C=CC1=CC=CN1 MZNSQRLUUXWLSB-UHFFFAOYSA-N 0.000 description 1
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- CUXGDKOCSSIRKK-UHFFFAOYSA-N 7-methyloctyl prop-2-enoate Chemical compound CC(C)CCCCCCOC(=O)C=C CUXGDKOCSSIRKK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241001117244 Chamaecyparis formosensis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920003182 Surlyn® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000736892 Thujopsis dolabrata Species 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 229920002978 Vinylon Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- NPTQTLMUAAVGNU-UHFFFAOYSA-N decyl 2-ethylhexanoate Chemical compound CCCCCCCCCCOC(=O)C(CC)CCCC NPTQTLMUAAVGNU-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KWABLUYIOFEZOY-UHFFFAOYSA-N dioctyl butanedioate Chemical compound CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC KWABLUYIOFEZOY-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- MZSJGCPBOVTKHR-UHFFFAOYSA-N isothiocyanatocyclohexane Chemical compound S=C=NC1CCCCC1 MZSJGCPBOVTKHR-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 description 1
- 229960003926 methylrosaniline Drugs 0.000 description 1
- QFVDKARCPMTZCS-UHFFFAOYSA-N methylrosaniline Chemical compound C1=CC(N(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 QFVDKARCPMTZCS-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- YRVUCYWJQFRCOB-UHFFFAOYSA-N n-butylprop-2-enamide Chemical group CCCCNC(=O)C=C YRVUCYWJQFRCOB-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- MDYPDLBFDATSCF-UHFFFAOYSA-N nonyl prop-2-enoate Chemical compound CCCCCCCCCOC(=O)C=C MDYPDLBFDATSCF-UHFFFAOYSA-N 0.000 description 1
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UIIIBRHUICCMAI-UHFFFAOYSA-N prop-2-ene-1-sulfonic acid Chemical compound OS(=O)(=O)CC=C UIIIBRHUICCMAI-UHFFFAOYSA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 150000003152 propanolamines Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229960001975 sulfisomidine Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
本発明は、粘着性抗菌シートの使用方法に関し、詳しくは揮散性抗菌剤により、粘着性抗菌シートと被着体間に発生する空間に対して抗菌作用を発揮させる抗菌方法に関するものである。 The present invention relates to a method for using an adhesive antibacterial sheet, and more particularly to an antibacterial method for exerting an antibacterial effect on a space generated between an adhesive antibacterial sheet and an adherend with a volatile antibacterial agent.
従来から、皮膚面に貼付して使用する医療用粘着シートとして、粘着ドレッシング、巻絆創膏、救急絆創膏、粘着包帯や局所性薬物を含有するハップ剤、全身性薬物を含有する経皮吸収テープ製剤など種々のものが開発されている。これらの医療用貼付シートは、健常皮膚に貼付する場合には重要視されないが、損傷皮膚に貼付して創傷治癒に適用する場合には、たとえ製造時に滅菌処理などを施して密封包装していても、貼付後皮膚面に存在する菌の異常増殖や、外部からの菌の侵入によって創傷部が汚染されて、治癒を遅らせることが多く、時には院内感染の原因になることも考えられる。 Conventionally, adhesive dressings, wound bandages, emergency bandages, haptics containing adhesive bandages and topical drugs, transdermal tape preparations containing systemic drugs, etc., as adhesive sheets for medical use attached to the skin surface Various things have been developed. These medical patch sheets are not regarded as important when affixed to healthy skin, but when applied to wounded skin and applied to wound healing, they must be sterilized and sealed at the time of manufacture. However, wounds are often contaminated by the abnormal growth of bacteria present on the skin surface after application or the invasion of bacteria from outside, delaying healing, and sometimes causing nosocomial infections.
このような場合、貼付前に皮膚面を消毒したり、あるいは医療用貼付シートの粘着剤層や支持体層に抗菌剤を含有させたものが開発されている（特許文献１）。使用する抗菌剤としては抗菌スペクトルの広いものが一般的に使用され、例えば、エリスロマイシン、テトラサイクリン、クロラムフェニコール、フラジオマイシン、ストレプトマイシン等の抗生物質やビグアニド化合物、ベンザルコニウム、ジデシルシメチルアンモニウム等の表面活性を有する化合物や、フェノールやレゾルシン等のフェノール系化合物、ヨウ素やポビドンヨウ素等のヨウ素化合物、銀、銅等の金属類、アクリノール、メチルロザニリン等の抗菌色素化合物、スルファジアジン、スルフィソミジン等のサルファ剤等が使用されている。 In such a case, an antibacterial agent has been developed in which the skin surface is sterilized before application, or the pressure-sensitive adhesive layer or support layer of a medical patch sheet is incorporated (Patent Document 1). Antibacterial agents with a broad antibacterial spectrum are generally used. For example, antibiotics such as erythromycin, tetracycline, chloramphenicol, fradiomycin, streptomycin, biguanide compounds, benzalkonium, didecylcymethylammonium, etc. Surface active compounds, phenolic compounds such as phenol and resorcin, iodine compounds such as iodine and povidone iodine, metals such as silver and copper, antibacterial pigment compounds such as acrinol and methylrosaniline, sulfa drugs such as sulfadiazine and sulfisomidine Is used.
しかし、上記のように医療用粘着シートを皮膚面に貼付する場合は、合成物よりも天然物由来の抗菌剤を用いるほうが刺激性も少なく、好ましい。近年は天然物由来の抗菌剤である台湾ヒノキや青森ヒバの精油中に含まれるヒノキチオールが、広い抗菌スペクトルと高い抗菌活性と耐性菌を作りにくいといった点で注目されている。 However, when the medical adhesive sheet is applied to the skin surface as described above, it is preferable to use an antibacterial agent derived from a natural product rather than a synthetic product because it is less irritating. In recent years, hinokithiol contained in essential oils of Taiwan Hinoki and Aomori Hiba, which are antibacterial agents derived from natural products, has been attracting attention because of its wide antibacterial spectrum, high antibacterial activity and resistance to resistant bacteria.
ヒノキチオールのような揮散性抗菌剤を含有させた粘着シートは、ヒノキチオールが加熱工程で揮散しやすいので製造工程において非常に取り扱いにくい。さらにヒノキチオールは光に対しても不安定であり、分散速度も速いことから、製造後であっても取り扱いにくく、製造時、保存時の安定性確保と使用時の放出制御は非常に困難であった。シクロデキストリン等による包接化合物とした揮散性抗菌剤を含有する抗菌性液について開示がある（特許文献２）。また、ヒノキチオールにおける揮散性、安定性の問題を改良するために、シクロデキストリン等の包接化合物とした抗菌剤を含有する粘着性抗菌シートについても開示がある（特許文献３）。 A pressure-sensitive adhesive sheet containing a volatile antibacterial agent such as hinokitiol is very difficult to handle in the manufacturing process because hinokitiol is easily volatilized in the heating process. Furthermore, hinokitiol is unstable to light and has a high dispersion rate, so it is difficult to handle even after production, and it is very difficult to ensure stability during production and storage and to control release during use. It was. There is a disclosure about an antibacterial liquid containing a volatile antibacterial agent as an inclusion compound such as cyclodextrin (Patent Document 2). Moreover, in order to improve the problem of volatility and stability in hinokitiol, there is also disclosed an adhesive antibacterial sheet containing an antibacterial agent as an inclusion compound such as cyclodextrin (Patent Document 3).
医療用粘着シートは、損傷皮膚に貼付して創傷治癒に適用する場合の他、例えば輸液製剤の注入時における注射針の固定や、カテーテル挿入時の固定などのために適用される場合がある。このように医療用具の固定に粘着シートを使用する場合は、皮膚面、特に注射針等の皮膚内部への挿入局所に粘着シートが直接接触する場合は殆どなく、粘着シートは挿入局所部位では浮き上がった状態になっている。このような場合においても、挿入局所における汚染を排除するために、粘着シートと皮膚面の間においても抗菌効果が発揮されることが期待される。特許文献３では、粘着性抗菌シートの支持体背面からの空間的な抗菌効果については記載されているが、粘着シートと皮膚面の間における抗菌効果については具体的な検討はなされていない。
本発明は、粘着性抗菌シートを使用することによる効果的な抗菌方法を提供することを課題とする。例えば、注射針の固定等に粘着性抗菌シートを使用する場合等において、皮膚面から該抗菌シートが浮き上がった状態でも、粘着性抗菌シートの面と皮膚面の間において抗菌効果が発揮されうる抗菌方法を提供することを課題とする。 An object of the present invention is to provide an effective antibacterial method by using an adhesive antibacterial sheet. For example, when an adhesive antibacterial sheet is used for fixing an injection needle or the like, an antibacterial effect can be exerted between the surface of the adhesive antibacterial sheet and the skin surface even when the antibacterial sheet is lifted from the skin surface. It is an object to provide a method.
本発明者らは、上記目的を達成すべく鋭意検討を重ねた結果、揮散性抗菌剤が揮散する点に着目し、支持体の片面に揮散性抗菌剤を含有する非水系粘着剤層が形成された粘着性抗菌シートを使用することで、粘着性抗菌シートの面から被着体に至るまでの空間および該空間に接する被着体の表面が効果的に抗菌されることを見出し本発明を完成するに至った。 As a result of intensive studies to achieve the above object, the present inventors have focused on the point that the volatile antibacterial agent is volatilized, and a non-aqueous pressure-sensitive adhesive layer containing the volatile antibacterial agent is formed on one side of the support. The present invention finds that the space from the surface of the adhesive antibacterial sheet to the adherend and the surface of the adherend in contact with the space are effectively antibacterized by using the adhesive antibacterial sheet thus prepared. It came to be completed.
即ち本発明は、以下よりなる。
１．支持体の片面に、揮散性抗菌剤およびその包接体を含有する非水系粘着剤層が形成された粘着性抗菌シートを使用し、該粘着性抗菌シートと被着体との間に空間を設け、粘着性抗菌シートの粘着剤層面から揮散性抗菌剤を揮散させ、粘着性抗菌シートの面から被着体に至るまでの空間および該空間に接する被着体の表面を抗菌することを特徴とする抗菌方法。
２．透湿度が少なくとも８００ｇ／ｍ２・２４ｈｒｓ以上であり、支持体に紫外線吸収剤を含有させてなる粘着性抗菌シートを使用する前項１に記載の抗菌方法。
３．支持体が着色されてなる粘着性抗菌シートを使用する前項１または２に記載の抗菌方法。
４．含有する揮散性抗菌剤がヒノキチオールである前項１〜３のいずれか一項に記載の抗菌方法。
That is, this invention consists of the following.
1. Using a pressure-sensitive antibacterial sheet in which a non-aqueous pressure-sensitive adhesive layer containing a volatile antibacterial agent and its inclusion is formed on one side of the support, a space is provided between the pressure-sensitive antibacterial sheet and the adherend. It is characterized by volatilizing the volatile antibacterial agent from the adhesive layer surface of the adhesive antibacterial sheet, and antibacterial the space from the surface of the adhesive antibacterial sheet to the adherend and the surface of the adherend in contact with the space Antibacterial method.
2. 2. The antibacterial method according to item 1 above, wherein an adhesive antibacterial sheet having a moisture permeability of at least 800 g / m 2 · 24 hrs or more and containing a UV absorber in the support is used.
3. 3. The antibacterial method according to item 1 or 2, wherein an adhesive antibacterial sheet having a colored support is used.
4). 4. The antibacterial method according to any one of items 1 to 3, wherein the volatile antibacterial agent to be contained is hinokitiol.
本発明の抗菌方法によると、粘着性抗菌シートの面から揮散する抗菌剤によって、粘着剤層に対峙する特定の部位が効果的に抗菌される。例えば輸液製剤の注入時における注射針の固定や、カテーテル挿入時の固定など医療用具の固定に使用する場合、粘着性抗菌シートの面から皮膚までの空間ならびに皮膚面、医療用具、特に注射針等の皮膚内部への挿入局所が効果的に抗菌される。これにより、粘着性抗菌シートと皮膚の間に空間が生じる場合であっても、外部から菌が侵入することがなく、院内感染などの菌感染を防ぐことができる。特に、支持体に紫外線吸収剤を添加したり、着色した支持体を用いることによって、揮散性抗菌剤の光に対する安定性を向上させることにより、より効果的に抗菌効果を持続させることができる。 According to the antibacterial method of the present invention, the specific part facing the adhesive layer is effectively antibacterial by the antibacterial agent evaporating from the surface of the adhesive antibacterial sheet. For example, when used to fix a medical device such as fixing an injection needle at the time of injection of an infusion preparation or a catheter, the space from the surface of the adhesive antibacterial sheet to the skin, the skin surface, a medical device, particularly an injection needle, etc. The inside of the skin is effectively antibacterial. Thereby, even if it is a case where a space arises between an adhesive antibacterial sheet and skin, bacteria do not penetrate | invade from the outside and bacteria infections, such as nosocomial infection, can be prevented. In particular, the antibacterial effect can be maintained more effectively by improving the stability of the volatile antibacterial agent to light by adding an ultraviolet absorber to the support or using a colored support.
本発明において、「被着体」とは、粘着性抗菌シートが皮膚に直接貼付されている部位に限定されず、粘着性抗菌シートが接着するカテーテル等の医療用具も含まれる。皮膚面が粘着性抗菌シートで覆われている場合において、該抗菌シートと皮膚面との間に空間がある場合の皮膚面も「被着体」という。例えば医療用具等の固定のために使用する場合、医療用具により粘着性抗菌シートが皮膚から浮き上がった状態になる部分がある。このような場合においても、該抗菌シートに覆われている皮膚部位は、本発明において「被着体」という。また、医療用具の固定に限らず、例えばドレッシング剤の使用等において、皮膚貼付時によれが生じたために皮膚面から粘着性抗菌シートが浮き上がった部分がある場合においても同様である。
また、本発明において、「抗菌シートの面」とは、抗菌シートに抗菌剤が形成されている面、すなわち「抗菌シートの粘着剤層側の面」を意味する。
In the present invention, the “adherent” is not limited to the site where the adhesive antibacterial sheet is directly attached to the skin, but also includes medical devices such as a catheter to which the adhesive antibacterial sheet adheres. When the skin surface is covered with an adhesive antibacterial sheet, the skin surface when there is a space between the antibacterial sheet and the skin surface is also referred to as an “adherent”. For example, when used for fixing a medical device or the like, there is a portion where the adhesive antimicrobial sheet is lifted from the skin by the medical device. Even in such a case, the skin part covered with the antibacterial sheet is referred to as an “adherent” in the present invention. The same applies not only to the fixing of medical devices, but also when there is a part where the adhesive antibacterial sheet has been lifted from the skin surface due to the occurrence of kinking when using a dressing agent, for example.
In the present invention, the “surface of the antibacterial sheet” means a surface where the antibacterial agent is formed on the antibacterial sheet, that is, “surface of the antibacterial sheet on the pressure-sensitive adhesive layer side”.
本発明の抗菌方法に使用される粘着性抗菌シートの支持体として、例えば、無孔のプラスチックシート、多孔質プラスチックシート、または不織布を用いることができる。支持体背面から揮散性抗菌剤が揮散するのを防ぐため、無孔のプラスチックシートを使用するのが最も好適である。 As a support for the adhesive antibacterial sheet used in the antibacterial method of the present invention, for example, a non-porous plastic sheet, a porous plastic sheet, or a nonwoven fabric can be used. In order to prevent volatilization of the volatile antibacterial agent from the back of the support, it is most preferable to use a non-porous plastic sheet.
支持体に使用される無孔のプラスチックシートとして、具体的には、ポリエチレン、ポリプロピレン、エチレン／酢酸ビニル共重合体、ポリエチレン／エチルアクリレート共重合体、ポリテトラフルオロエチレン等のポリオレフィン系樹脂、ポリエチレンテレフタレート等のポリエステル系樹脂、ポリエーテルポリウレタンやポリエステルポリウレタン等のポリウレタン系樹脂、ナイロン、ポリエーテルポリアミドブロック共重合体等のポリアミド系樹脂、ポリ塩化ビニル、サラン、サーリン等のプラスチック材料からなるものが挙げられる。 Specific examples of the non-porous plastic sheet used in the support include polyethylene, polypropylene, ethylene / vinyl acetate copolymer, polyethylene / ethyl acrylate copolymer, polyolefin resin such as polytetrafluoroethylene, and polyethylene terephthalate. Polyester resins such as polyether polyurethane and polyester polyurethane, polyamide resins such as nylon and polyether polyamide block copolymers, and those made of plastic materials such as polyvinyl chloride, saran and surlyn. .
例えば、被着体から水分が出る場合は、皮膚面を適度な湿度に保つため、透湿度を８００ｇ／ｍ２・２４ｈｒｓ以上、好ましくは１０００〜４０００ｇ／ｍ２・２４ｈｒｓ、さらに好ましくは１０００〜２０００ｇ／ｍ２・２４ｈｒｓとするのが好適である。このような透湿度を有する無孔のプラスチックシートとして、好適には、ポリエーテルポリウレタン等のポリウレタン系樹脂や、ポリエーテルポリアミドブロック共重合体等のポリアミド系樹脂を用いることができ、これらは透湿度だけでなく、柔軟性を有するので皮膚面に貼付した際の違和感が生じず好ましいものである。 For example, if from the adherend moisture out is to keep the skin surface to moderate humidity, the moisture permeability 800g / m 2 · 24hrs or more, preferably 1000~4000g / m 2 · 24hrs, more preferably 1000~2000g / M 2 · 24 hrs is preferable. As the non-porous plastic sheet having such a moisture permeability, a polyurethane resin such as polyether polyurethane or a polyamide resin such as polyether polyamide block copolymer can be preferably used. In addition, since it has flexibility, it does not cause a sense of incongruity when applied to the skin surface, which is preferable.
支持体に使用される多孔質プラスチックシートとして、上記した無孔のプラスチックシートと同様の材料からなるものを用いることができる。多孔質化手段としては、無孔のプラスチックシートに穿孔処理を施したり、シートの製造工程で公知の多孔質化処理、例えば無機粉末や有機溶剤をシート化材料中に配合した後、シート化し、これを必要に応じて延伸処理して、最後に有機溶剤や無機粉末を抽出して多孔質化する等の処理を施してもよい。 As the porous plastic sheet used for the support, one made of the same material as the non-porous plastic sheet described above can be used. As a porous means, a perforated plastic sheet is subjected to perforation processing, or a known porous processing in a sheet manufacturing process, for example, an inorganic powder or an organic solvent is blended in a sheet forming material, and then sheeted. This may be subjected to a stretching treatment as necessary, and finally, an organic solvent or an inorganic powder is extracted to make it porous.
なお、前記無孔のプラスチックシートや上記多孔質プラスチックシートを支持体に用いた場合には、皮膚面、特に関節部等の皮膚の動きが大きい部位に貼付した際に違和感を生じなくするために、その厚みを１０〜１００μｍ、好ましくは２０〜５０μｍ程度にすることが好ましく、皮膚面貼付中の皮膚の動きに追従するためには、引張強度を１００〜９００ｋｇ／ｃｍ２、１００％モジュラスを１０〜１００ｋｇ／ｃｍ２程度に調整することが好ましい。 In addition, when the non-porous plastic sheet or the porous plastic sheet is used as a support, in order to prevent a sense of incongruity when affixed to a skin surface, particularly a site where skin movement is large, such as a joint part. The thickness is preferably about 10 to 100 μm, preferably about 20 to 50 μm. In order to follow the movement of the skin during skin surface application, the tensile strength is 100 to 900 kg / cm 2 , and the 100% modulus is 10 it is preferably adjusted to about to 100 kg / cm 2.
支持体に使用される不織布として、具体的にはポリエチレンやポリプロピレン等のポリオレフィン系樹脂、ポリエチレンテレフタレート等のポリエステル系樹脂、レーヨン、ナイロン、ビニロン、キュプラ等の各種プラスチック材料からなる不織布や、パルプ不織布等が挙げられる。また、使用する不織布は、粘着性抗菌シートの製造時や貼付操作時の取扱性や貼付中の違和感の点からは、５〜１００ｇ／ｍ２、好ましくは２４〜４５ｇ／ｍ２の坪量を有するものを用いることが望ましい。坪量が小さすぎると自己支持性に欠けるようになって取扱性が低下し、坪量が大き過ぎると柔軟性にかけて、貼付した皮膚面にゴワゴワ感（違和感）を与えるようになる。 Nonwoven fabrics used for the support, specifically, polyolefin resins such as polyethylene and polypropylene, polyester resins such as polyethylene terephthalate, nonwoven fabrics made of various plastic materials such as rayon, nylon, vinylon, and cupra, and pulp nonwoven fabrics Is mentioned. Further, the nonwoven fabric to be used from the viewpoint of discomfort of handling and pasting in during manufacture or affixed operation of the adhesive antimicrobial sheet is 5 to 100 g / m 2, preferably at a basis weight of 24~45g / m 2 It is desirable to use what has. If the basis weight is too small, the self-supporting property will be lost, and the handleability will be reduced. If the basis weight is too large, the flexibility will be applied and the skin surface will be irritated (uncomfortable).
本発明の抗菌方法に使用される粘着性抗菌シートの粘着剤層は、上記した支持体の片面に形成されるものであって、揮散性抗菌剤を含有、保持するものであり、実質的に水を含有しない非水系の粘着剤から形成される。なお、「実質的に水を含有しない」とは、製造工程で意識的に水を含有させないという意味であり、粘着剤層が空気中に曝された場合に自然に吸湿する水分をも含有しないという意味ではない。本発明では粘着剤層中に水が存在すると、含有する揮散性抗菌剤が熱や光によって不安定化することを促進する恐れがある。特に揮散性抗菌剤がシクロデキストリン（以下単に「ＣＤ」という場合がある。）等で包接されていたり、塩形態になっている場合には、粘着剤層中の水分の存在によって、保存中に遊離体の揮散性抗菌剤になりやすくなり、使用するまでに揮散性抗菌剤の含有量低下をおこすおそれがある。 The pressure-sensitive adhesive layer of the pressure-sensitive antibacterial sheet used in the antibacterial method of the present invention is formed on one side of the above-described support and contains and holds a volatile antibacterial agent. It is formed from a non-aqueous adhesive that does not contain water. In addition, “substantially no water” means that water is not intentionally contained in the production process, and does not contain water that naturally absorbs moisture when the pressure-sensitive adhesive layer is exposed to the air. It does not mean that. In this invention, when water exists in an adhesive layer, there exists a possibility of promoting that the volatile antimicrobial agent to contain destabilizes with a heat | fever or light. In particular, if the volatile antibacterial agent is included in a cyclodextrin (hereinafter sometimes referred to simply as “CD”) or is in a salt form, it is stored due to the presence of moisture in the adhesive layer. It becomes easy to become a volatile antibacterial agent in a free form, and there is a possibility that the content of the volatile antibacterial agent is lowered before use.
このような粘着剤層を形成する非水系粘着剤としては、アクリル系粘着剤や天然ゴム系粘着剤、合成ゴム系粘着剤、シリコーン系粘着剤、ビニルエーテル系粘着剤、ポリエステル系粘着剤等の粘着剤を用いることができ、これらのうち、粘着剤の品質の安定性や、粘着特性の制御容易性、粘着特性の長期安定性、皮膚に対する無刺激性などの点からアクリル系粘着剤を用いることが好ましい。アクリル系粘着剤としては、（メタ）アクリル酸アルキルエステルを主成分単量体として、これに共重合性の単量体を共重合させてなる共重合体を用いることが好ましい。 Non-aqueous adhesives that form such an adhesive layer include acrylic adhesives, natural rubber adhesives, synthetic rubber adhesives, silicone adhesives, vinyl ether adhesives, polyester adhesives, and the like. Among them, acrylic adhesives should be used from the viewpoints of stability of adhesive quality, ease of control of adhesive properties, long-term stability of adhesive properties, and non-irritating properties to the skin. Is preferred. As the acrylic pressure-sensitive adhesive, it is preferable to use a copolymer obtained by copolymerizing a (meth) acrylic acid alkyl ester as a main component monomer and a copolymerizable monomer.
（メタ）アクリル酸アルキルエステルとしては、具体的には、アクリル酸やメタクリル酸に炭素数が１〜１８、好ましくは４〜１２のアルコールがエステル結合したものが使用できる。好ましい具体例としては、（メタ）アクリル酸ブチルエステルや、（メタ）アクリル酸ペンチルエステル、（メタ）アクリル酸ヘキシルエステル、（メタ）アクリル酸ヘプチルエステル、（メタ）アクリル酸オクチルエステル、（メタ）アクリル酸ノニルエステル、（メタ）アクリル酸デシルエステル、（メタ）アクリル酸ドデシルエステル等が挙げられる。これらのうち、優れた粘着特性を発揮するものとして、アルキル基の炭素数が６以上、特に６〜１８の長鎖アルキルエステルを有する（メタ）アクリル酸アルキルエステルを用いることが好ましい。なお、本発明における上記（メタ）アクリル酸アルキルエステルのアルキルエステル鎖は、直鎖状だけでなく、構造異性体としての分岐鎖状のものも含むことは云うまでもない。 As (meth) acrylic acid alkyl ester, specifically, an acrylic acid or methacrylic acid in which an alcohol having 1 to 18, preferably 4 to 12 carbon atoms is ester-bonded can be used. Preferred examples include (meth) acrylic acid butyl ester, (meth) acrylic acid pentyl ester, (meth) acrylic acid hexyl ester, (meth) acrylic acid heptyl ester, (meth) acrylic acid octyl ester, (meth) Examples include acrylic acid nonyl ester, (meth) acrylic acid decyl ester, (meth) acrylic acid dodecyl ester, and the like. Among these, it is preferable to use (meth) acrylic acid alkyl ester having a long-chain alkyl ester having 6 or more carbon atoms, particularly 6 to 18 carbon atoms, as a material exhibiting excellent adhesive properties. In addition, it cannot be overemphasized that the alkyl ester chain | strand of the said (meth) acrylic-acid alkylester in this invention contains not only a linear form but the branched chain form as a structural isomer.
一方、上記（メタ）アクリル酸アルキルエステルは一種からなる単独重合体、もしくは二種以上を組み合わせてなる共重合体として粘着剤とすることもできるが、皮膚接着性や内部凝集性、タック（粘着性）等の粘着特性を容易に調整するためには、共重合性単量体を共重合することが好ましい。このような共重合性単量体としては、分子内にカルボキシル基やスルホニル基、アミノ基、アミド基、ビニルエステル基、アルコシキル基、ヒドロキシル基等を有する単量体を用いることができる。具体的には、アクリル酸やメタクリル酸、イタコン酸、クロトン酸、マレイン酸、フマール酸、メサコン酸、シトラコン酸、グルタコン酸等のカルボキシル基含有単量体や、スチレンスルホン酸、アリルスルホン酸、（メタ）アクリル酸スルホプロピルエステル等のスルホキシル基含有単量体、（メタ）アクリル酸アミノエチルエステル、（メタ）アクリル酸ジメチルアミノエチルエステル、（メタ）アクリル酸ｔｅｒｔ−ブチルアミノエチルエステル等のアミノ基含有単量体、アクリルアミドやメタクリルアミド、Ｎ−ビニル−２−ピロリドン、ジメチル（メタ）アクリルアミド、Ｎ−ブチルアクリルアミド等のアミド基含有単量体、酢酸ビニルやプロピオン酸ビニル等のビニルエステル基含有単量体、（メタ）アクリル酸メトシキポリエチレングリコール、（メタ）アクリル酸エトキシジエチレングリコール、（メタ）アクリル酸ブトキシジエチレングリコール、（メタ）アクリル酸メトキシエチル、（メタ）アクリル酸エトキシエチル等のアルコキシ基含有単量体、（メタ）アクリル酸ヒドロキシエチルエステルや（メタ）アクリル酸ヒドロキシプロピルエステル等のヒドロキシル基含有単量体の他、ビニルピリジンやビニルピロール、ビニルイミダゾール等のビニルアミン類、アクリロニトリルやスチレン等の単量体を一種もしくは二種以上を併用して用いることができる。 On the other hand, the (meth) acrylic acid alkyl ester can be used as a pressure-sensitive adhesive as a single polymer or a copolymer of two or more types. In order to easily adjust the adhesive properties such as property, it is preferable to copolymerize a copolymerizable monomer. As such a copolymerizable monomer, a monomer having a carboxyl group, a sulfonyl group, an amino group, an amide group, a vinyl ester group, an alkoxyl group, a hydroxyl group or the like in the molecule can be used. Specifically, carboxyl group-containing monomers such as acrylic acid, methacrylic acid, itaconic acid, crotonic acid, maleic acid, fumaric acid, mesaconic acid, citraconic acid, glutaconic acid, styrene sulfonic acid, allyl sulfonic acid, ( Sulfoxyl group-containing monomers such as (meth) acrylic acid sulfopropyl ester, amino groups such as (meth) acrylic acid aminoethyl ester, (meth) acrylic acid dimethylaminoethyl ester, (meth) acrylic acid tert-butylaminoethyl ester Containing monomers, amide group-containing monomers such as acrylamide, methacrylamide, N-vinyl-2-pyrrolidone, dimethyl (meth) acrylamide, N-butyl acrylamide, vinyl ester group-containing monomers such as vinyl acetate and vinyl propionate Mer, methoxypolyether (meth) acrylate Alkylene group-containing monomers such as lenglycol, ethoxydiethylene glycol (meth) acrylate, butoxydiethylene glycol (meth) acrylate, methoxyethyl (meth) acrylate, ethoxyethyl (meth) acrylate, hydroxyethyl (meth) acrylate In addition to hydroxyl group-containing monomers such as esters and hydroxypropyl esters of (meth) acrylic acid, vinylamines such as vinylpyridine, vinylpyrrole and vinylimidazole, and monomers such as acrylonitrile and styrene are used alone or in combination. Can be used.
これらの共重合性単量体は、前記の（メタ）アクリル酸アルキルエステル４０〜９７重量％に対して、３〜６０重量％、好ましくは（メタ）アクリル酸アルキルエステル６０〜９５重量％に対して５〜４０重量％の範囲で共重合することで、本発明に用いる粘着特性に優れた粘着剤を調製することができる。 These copolymerizable monomers are 3 to 60% by weight, preferably 60 to 95% by weight of the (meth) acrylic acid alkyl ester, based on 40 to 97% by weight of the (meth) acrylic acid alkyl ester. By copolymerizing within a range of 5 to 40% by weight, a pressure-sensitive adhesive having excellent adhesive properties used in the present invention can be prepared.
上記した粘着剤には、必要に応じて自体公知の可塑剤や軟化剤、充填剤、粘着付与剤等の添加剤を適宜配合することができる。粘着剤層の低変形領域でのモジュラスを低下させて、粘着性抗菌シートの皮膚接着性を良好にすると共に、該抗菌シートを皮膚面から剥離除去する際に角質損傷が少なく、痛みも低減するようにするために、脂肪酸エステルを含有させることが好ましい。 If necessary, additives such as plasticizers, softeners, fillers, tackifiers and the like known per se can be appropriately blended with the above-mentioned pressure-sensitive adhesive. Reduces the modulus of the adhesive layer in the low-deformation region to improve the adhesiveness of the adhesive antibacterial sheet, and reduces keratinous damage and reduces pain when the antibacterial sheet is peeled and removed from the skin surface. Therefore, it is preferable to contain a fatty acid ester.
含有させる脂肪酸エステルとして、上記した粘着剤の粘着特性を阻害し、粘着特性のバラツキを生じないようにするために、粘着剤と親和性や相溶性を有するものが好ましい。具体的には、ミリスチン酸エチル、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、ステアリン酸ブチル、イソステアリン酸イソプロピル、ラウリン酸ヘキシル、乳酸セチル、乳酸ミリスチル、フタル酸ジエチル、ミリスチン酸オクチルドデシル、オレイン酸オクチルドデシル、ジメチルオクタン酸ヘキシルデシル、２−エチルヘキサン酸デシル、２−エチルヘキサン酸イソセチル、２−エチルヘキサン酸ステアリル、コハク酸ジオクチル等の一価アルコールを用いたカルボン酸エステル、ジカプリン酸プロピレングリコール、ジカプリン酸プロピレングリコール、ジイソステアリン酸プロピレングリコール、モノカプリル酸グリセリル、トリカプリル酸グリセリル、トリ２−エチルヘキサン酸グリセリル、トリカプリン酸グリセリル、トリラウリン酸グリセリル、トリイソステアリン酸グリセリル、トリオレイン酸グリセリル、トリ２−エチルヘキサン酸トリメチロールプロパン等の二価以上の多価アルコールを用いたカルボン酸エステルを用いることができる。 As the fatty acid ester to be contained, those having affinity or compatibility with the pressure-sensitive adhesive are preferred in order to inhibit the pressure-sensitive adhesive properties of the above-mentioned pressure-sensitive adhesive and prevent variations in the pressure-sensitive adhesive properties. Specifically, ethyl myristate, isopropyl myristate, isopropyl palmitate, butyl stearate, isopropyl isostearate, hexyl laurate, cetyl lactate, myristyl lactate, diethyl phthalate, octyldodecyl myristate, octyldodecyl oleate, dimethyl Hexyldecyl octanoate, decyl 2-ethylhexanoate, isocetyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, dioctyl succinate, etc., carboxylic acid esters, propylene glycol dicaprate, propylene glycol dicaprate , Propylene glycol diisostearate, glyceryl monocaprylate, glyceryl tricaprylate, glyceryl tri-2-ethylhexanoate, glyceryl tricaprate It can be used trilaurate, glyceryl triisostearate, glyceryl trioleate, glyceryl, carboxylic acid ester with a polyhydric alcohol having two or more valencies such as tri-2-ethylhexanoate trimethylolpropane.
これらの脂肪酸エステルのうち、酸化劣化が少ないものとして、脂肪酸中に不飽和結合を有さない飽和脂肪酸とグリセリンとのエステルを用いることが、品質の安定性の点から好ましい。特に、カプリル酸やカプリン酸、２−エチルヘキサン酸のトリグリセリンエステルを用いることが好適である。 Among these fatty acid esters, it is preferable from the viewpoint of quality stability to use an ester of a saturated fatty acid and a glycerin that does not have an unsaturated bond in the fatty acid, as one having little oxidative degradation. In particular, it is preferable to use caprylic acid, capric acid, or triglycerin ester of 2-ethylhexanoic acid.
上記脂肪酸エステルは、その一種もしくは二種以上を併用して前記粘着剤、特にアクリル系共重合体と共に配合して粘着剤層を形成する成分とするが、その配合量は、アクリル系共重合体１００重量部に対して２０〜１２０重量部、好ましくは３０〜１００重量部の範囲に調整する。脂肪酸エステルの配合量が少なすぎると、皮膚面に本発明の粘着性抗菌シートを貼着した場合、皮膚面からの発汗を充分に粘着剤層が吸収できず、皮膚接着性の低下を招く恐れがある。また、脂肪酸エステルの配合量が多すぎると、粘着剤層が可塑化されすぎて皮膚接着力が大きく低下することがある。 The fatty acid ester is used as a component to form a pressure-sensitive adhesive layer by combining one or two or more of them together with the pressure-sensitive adhesive, particularly an acrylic copolymer. The amount of the fatty acid ester is an acrylic copolymer. The amount is adjusted to 20 to 120 parts by weight, preferably 30 to 100 parts by weight with respect to 100 parts by weight. If the amount of the fatty acid ester is too small, when the adhesive antibacterial sheet of the present invention is applied to the skin surface, the adhesive layer cannot sufficiently absorb sweat from the skin surface, which may lead to a decrease in skin adhesiveness. There is. Moreover, when there are too many compounding quantities of fatty acid ester, an adhesive layer will be plasticized too much and skin adhesive force may fall large.
上記した脂肪酸エステルを粘着剤中に配合する場合、脂肪酸エステルの保持性を向上させ、しかも粘着剤層の皮膚接着力と内部凝集力のバランスをとるために、粘着剤に架橋処理を施すことが好ましい。架橋処理としては、脂肪酸エステルを確実に保持するために粘着剤を構成する高分子間に適度な自由空間を確保するように、有機過酸化物やイソシアネート化合物、エポキシ系化合物、金属キレート化合物等の有機化合物を用いた分子間架橋剤を用いた化学的架橋処理や電離性放射線照射による物理的架橋処理を施すことが好ましい。化学的架橋処理としては、具体的には過酸化ベンゾイル等の有機過酸化物、トリレンジイソシアネート、ヘキサメチレンジイソシアネート等のイソシアネート化合物や多官能性イソシアネート化合物、グリセリントリグリシジルエーテル、トリグリシジルイソシアヌレート等のエポキシ系化合物、アルミニウムトリス（アセチルアセトネート）、エチルアセトアセテートアルミニウムジイソプロピレート等の金属キレート化合物が挙げられる。これらのうち、架橋反応性や取扱容易性の点から、イソシアネート化合物や多官能性イソシアネート化合物、金属キレート化合物を用いることが好ましい。 When the above fatty acid ester is blended in the pressure-sensitive adhesive, the pressure-sensitive adhesive may be subjected to a crosslinking treatment in order to improve the retention of the fatty acid ester and balance the adhesive strength of the skin and the internal cohesive force. preferable. As the crosslinking treatment, an organic peroxide, an isocyanate compound, an epoxy compound, a metal chelate compound, etc. are used to ensure an appropriate free space between the polymers constituting the pressure-sensitive adhesive in order to securely hold the fatty acid ester. It is preferable to perform a chemical crosslinking treatment using an intermolecular crosslinking agent using an organic compound or a physical crosslinking treatment by ionizing radiation irradiation. Specific examples of the chemical crosslinking treatment include organic peroxides such as benzoyl peroxide, isocyanate compounds such as tolylene diisocyanate and hexamethylene diisocyanate, polyfunctional isocyanate compounds, glycerin triglycidyl ether, and triglycidyl isocyanurate. Examples of the metal chelate compound include epoxy compounds, aluminum tris (acetylacetonate), and ethyl acetoacetate aluminum diisopropylate. Among these, it is preferable to use an isocyanate compound, a polyfunctional isocyanate compound, or a metal chelate compound from the viewpoint of cross-linking reactivity and ease of handling.
一方、物理的架橋処理としては、電子線やγ線、Ｘ線等を照射処理する方法が挙げられ、安全性や取扱性の点からは電子線やγ線を用いることが好ましい。照射線量としては１５〜５０ｋＧｙ、好ましくは２０〜３５ｋＧｙとする。なお、電離性放射線を照射することによって、粘着剤に架橋処理を施すだけでなく、所謂滅菌処理も施すことができるので、本発明のような皮膚貼付用途においては極めて好都合である。 On the other hand, examples of the physical cross-linking treatment include a method of irradiating with an electron beam, γ-ray, X-ray or the like. From the viewpoint of safety and handling, it is preferable to use an electron beam or γ-ray. The irradiation dose is 15 to 50 kGy, preferably 20 to 35 kGy. In addition, by irradiating with ionizing radiation, the adhesive can be subjected not only to a crosslinking treatment but also to a so-called sterilization treatment, which is extremely advantageous in the application to the skin as in the present invention.
上記非水系粘着剤層中には、揮散性抗菌剤が含有される。
使用可能な揮散性抗菌剤は、殺菌作用や静菌作用等の抗菌作用と共に、揮散性を有するものであれば、特に限定されるものではない。具体的には、イソチオシアン酸エステル類、ユーカリ油、メントール、ローズマリー、ヒノキチオール等が挙げられる。揮散性抗菌剤は、非水系粘着剤層中に０．０１〜１０重量％程度の量で含有される。これらの揮散性抗菌剤のうち、イソチオシアン酸エステル類を主成分とする抽出物やヒノキチオール、特にヒノキチオールが、安全性や幅広い抗菌スペクトル、耐性菌を作りにくい、皮膚常在菌の増殖抑制性、空間抗菌性の点から好適である。
A volatile antibacterial agent is contained in the non-aqueous pressure-sensitive adhesive layer.
The volatile antibacterial agent that can be used is not particularly limited as long as it has volatility as well as antibacterial effects such as bactericidal action and bacteriostatic action. Specific examples include isothiocyanate esters, eucalyptus oil, menthol, rosemary, and hinokitiol. The volatile antibacterial agent is contained in the non-aqueous pressure-sensitive adhesive layer in an amount of about 0.01 to 10% by weight. Among these volatile antibacterial agents, extracts based on isothiocyanate esters and hinokitiol, especially hinokitiol, are safe and have a broad antibacterial spectrum, resistant to the formation of resistant bacteria, the ability to inhibit the growth of skin resident bacteria, and space It is preferable from the viewpoint of antibacterial properties.
イソチオシアン酸エステル類を主成分とする抽出物として、カラシやワサビの辛味成分であるイソチオシアン酸アリル、イソチオシアン酸フェニル、イソチオシアン酸メチル、イソチオシアン酸エチル、イソチオシアン酸プロピル、イソチオシアン酸イソプロピル、イソチオシアン酸ブチル、イソチオシアン酸イソブチル、イソチオシアン酸イソアミル、イソチオシアン酸ベンジル、イソチオシアン酸シクロヘキシル等を主成分とする抽出物を使用することができる。 Extracts mainly composed of isothiocyanates include allyl isothiocyanate, phenyl isothiocyanate, methyl isothiocyanate, ethyl isothiocyanate, propyl isothiocyanate, isopropyl isothiocyanate, butyl isothiocyanate, and isothiocyanate. An extract mainly composed of isobutyl acid, isoamyl isothiocyanate, benzyl isothiocyanate, cyclohexyl isothiocyanate and the like can be used.
また、ヒノキチオールは、台湾ヒノキやヒバ、アスナロ等の植物由来の精油から抽出された天然物であってもよく、化学合成品であってもよい。さらに、本発明に用いるヒノキチオールはフリー体だけでなく、塩形態であってもよい。具体的には、ナトリウム塩やカリウム塩、マグネシウム塩、カルシウム塩、銅塩、亜鉛塩に代表される金属塩のような無機塩や、エタノールアミン塩、ジエタノールアミン塩、プロパノールアミン塩、ピペラジン塩、ピペリジン塩、アルギニン塩、リジン塩、ヒスチジン塩等の有機塩等も用いることができる。 The hinokitiol may be a natural product extracted from plant-derived essential oils such as Taiwan cypress, hiba, and asunaro, or may be a chemically synthesized product. Furthermore, the hinokitiol used in the present invention may be in a salt form as well as a free form. Specifically, inorganic salts such as sodium salts, potassium salts, magnesium salts, calcium salts, copper salts, and metal salts represented by zinc salts, ethanolamine salts, diethanolamine salts, propanolamine salts, piperazine salts, piperidine Organic salts such as salts, arginine salts, lysine salts and histidine salts can also be used.
上記揮散性抗菌剤は、製造工程で揮散して含量安定性に乏しかったり、光分解性を有するので、化学修飾することが好適である。化学修飾は種々検討されているが、揮散抑制や酸化防止、光分解防止等の安定性向上、徐放性等のために、シクロデキストリン（ＣＤ）等を用いるのが好適である。ＣＤは熱等にも安定である。ＣＤを用いて揮散性抗菌剤を包接し、包接化合物として粘着剤層に含有させることができる。ＣＤによる包接化合物に含まれる揮散性抗菌剤は、水分の存在により遊離体の揮散性抗菌剤になる。例えば、被着体（皮膚）から水分が出る場合は、ＣＤによる包接化合物とすることで揮散性抗菌剤が効果的に揮散される。使用可能なＣＤとしては、α−ＣＤ、β−ＣＤ、γ−ＣＤ、メチル化ＣＤ、ヒドロキシプロピル化ＣＤ、モノアセチル化ＣＤ、トリアセチル化ＣＤ、モノクロロトリアジノ化ＣＤ、スルホブチル化ＣＤ、グリコシル，マルトシル化ＣＤ、ＣＤポリマー、アミノ化ＣＤ、ヒドロキシブテニルＣＤ、エポキシ化ＣＤ、４級アンモニウム化ＣＤ、メタクリル化ＣＤ、硫酸化ＣＤを用いることができるが、揮散性抗菌剤の包接性などの点からは、β−ＣＤが好ましい。なお、ＣＤは安全性も高く、上記揮散性抗菌剤の抗菌作用を安定してより有効に発揮させることができる。
一方、被着体から水分が出ない場合は、揮散性抗菌剤を効果的に揮散させるために、ＣＤで修飾する必要はない。しかし、ＣＤ等で包接しない場合は、熱安定性等の問題があるため、金属錯体化やマイクロカプセル化、シリカハイブリッド化等の化学修飾を行うのが好適である。
Since the volatile antibacterial agent is volatilized in the production process and has poor content stability or has photodegradability, it is preferably chemically modified. Various chemical modifications have been studied, but it is preferable to use cyclodextrin (CD) or the like in order to suppress volatilization, improve stability such as prevention of oxidation and photolysis, and provide sustained release. CD is stable to heat and the like. A volatile antibacterial agent can be clathrated using CD and contained in the pressure-sensitive adhesive layer as a clathrate compound. The volatilizing antibacterial agent contained in the inclusion compound by CD becomes a free volatilizing antibacterial agent due to the presence of moisture. For example, when moisture comes out from the adherend (skin), the volatile antibacterial agent is effectively volatilized by using a clathrate compound with CD. Usable CDs include α-CD, β-CD, γ-CD, methylated CD, hydroxypropylated CD, monoacetylated CD, triacetylated CD, monochlorotriazinated CD, sulfobutylated CD, glycosyl, Maltosylated CD, CD polymer, aminated CD, hydroxybutenyl CD, epoxidized CD, quaternary ammonium CD, methacrylic CD, sulfated CD can be used. From the viewpoint, β-CD is preferable. Note that CD has high safety and can stably exhibit the antibacterial action of the volatile antibacterial agent more effectively.
On the other hand, when moisture does not come out from the adherend, it is not necessary to modify with CD to effectively volatilize the volatile antibacterial agent. However, when there is no inclusion with CD or the like, there are problems such as thermal stability, so it is preferable to perform chemical modification such as metal complexation, microencapsulation, and silica hybridization.
揮散性抗菌剤の持続性の制御は、支持体材料の選択や、支持体において、無孔のプラスチックシート、多孔質プラスチックシートおよび／または不織布を積層する等により行うことができる。また、揮散性抗菌剤の光に対する安定性を向上させるために、支持体に紫外線吸収剤を添加したり、支持体を着色することができる。支持体は、茶色やオレンジ色、赤色系統に着色することができ、着色の方法は自体公知の方法を適用することができる。 The sustainability of the volatile antibacterial agent can be controlled by selecting a support material or laminating a nonporous plastic sheet, a porous plastic sheet and / or a nonwoven fabric on the support. Moreover, in order to improve the stability with respect to the light of a volatile antibacterial agent, an ultraviolet absorber can be added to a support body or a support body can be colored. The support can be colored brown, orange or red, and a method known per se can be applied.
粘着性抗菌シートを使用するまでの間に、揮散性抗菌剤が粘着剤層面から揮散するのを防ぐために、５００ｇ／ｍ２・２４ｈｒｓ以下、好ましくは２００ｇ／ｍ２・２４ｈｒｓ以下の透湿度を有する裏打シートを、さらに好ましくは実質的に透湿度を有さない裏打シートを剥離可能に積層することもできる。該裏打シートを積層している間は揮散性抗菌剤の揮散が抑制されているが、必要に応じてこの裏打シートを剥離除去することで、粘着剤層中に含有する揮散性抗菌剤を持続的に効率よく利用することができる。該裏打シートに紫外線吸収剤を添加してもよく、着色しても良い。
本発明に使用する粘着性抗菌シートは、使用単位ごとに個別包装してもよく、該包装材料に紫外線吸収剤を添加してもよい。また、遮光のために、包装材料は茶色やオレンジ色、赤色系統の着色材料とすることもできる。
In order to prevent the volatile antibacterial agent from evaporating from the adhesive layer surface until the adhesive antibacterial sheet is used, it has a moisture permeability of 500 g / m 2 · 24 hrs or less, preferably 200 g / m 2 · 24 hrs or less. The backing sheet, more preferably, the backing sheet having substantially no moisture permeability can be laminated so as to be peelable. While laminating the backing sheet, volatilization of the volatile antibacterial agent is suppressed, but the volatile antibacterial agent contained in the adhesive layer can be maintained by peeling and removing the backing sheet as necessary. Can be used efficiently. An ultraviolet absorber may be added to the backing sheet, or it may be colored.
The adhesive antibacterial sheet used in the present invention may be individually packaged for each unit used, and an ultraviolet absorber may be added to the packaging material. Further, for the purpose of light shielding, the packaging material may be a brown, orange or red colored material.
支持体、裏打シート、または包装材料等に含有されうる紫外線吸収剤は、医療用シートに適用可能なものであれば良く、自体公知のものを使用することができる。例えばベンゾフェノン系、トリアゾール系等の有機系紫外線吸収剤 あるいは微粒子状の酸化亜鉛、酸化チタン、酸化鉄等の無機系紫外線吸収剤が挙げられる。フィルムの透明性が要求される場合は有機系紫外線吸収剤が、透明性を要求されない場合はブリードアウトのない無機系の紫外線吸収剤が好ましく使用される。好ましい紫外線吸収剤として酸化チタンが挙げられる。紫外線吸収剤の配合量は特に制限されず、支持体等から溢れ出さない程度であればよく、例えば支持体、裏打シート、または包装材料等の樹脂成分１００重量部に対して、通常０．０１〜１０重量部程度、好ましくは０．０５〜５重量部である。 The ultraviolet absorber that can be contained in the support, the backing sheet, the packaging material, or the like is only required to be applicable to the medical sheet, and those known per se can be used. Examples thereof include organic ultraviolet absorbers such as benzophenone and triazole, and inorganic ultraviolet absorbers such as particulate zinc oxide, titanium oxide, and iron oxide. When the transparency of the film is required, an organic ultraviolet absorber is preferably used, and when the transparency is not required, an inorganic ultraviolet absorber without bleeding out is preferably used. A preferable ultraviolet absorber is titanium oxide. The blending amount of the ultraviolet absorber is not particularly limited as long as it does not overflow from the support or the like. For example, it is usually 0.01 with respect to 100 parts by weight of the resin component such as the support, the backing sheet, or the packaging material. About 10 to 10 parts by weight, preferably 0.05 to 5 parts by weight.
裏打シート、あるいは包装材料は、医療用シートに適用可能なものであれば良く、自体公知のものを使用することができる。各種プラスチックシートや金属箔、金属蒸着したプラスチックシート、プラスチックシートと金属箔との積層シート、プラスチックシートを積層した紙基材等を用いることができ、透湿度の制御は材質やシート厚みで行えばよい。裏打シートの場合、剥離可能に支持体背面に積層する手段としては、自体公知の方法を適用することができる。 The backing sheet or the packaging material may be any material that can be applied to a medical sheet, and a material known per se can be used. Various plastic sheets and metal foils, metal-deposited plastic sheets, laminated sheets of plastic sheets and metal foils, paper substrates laminated with plastic sheets, etc. can be used. Good. In the case of a backing sheet, a method known per se can be applied as a means for laminating the back surface of the support so as to be peelable.
上記により得られた粘着性抗菌シートを次のようにして使用し、被着体を抗菌することができる。粘着性抗菌シートを使用し、該抗菌シートと被着体との間に空間が設けられるように貼付する。
例えば、シリコンチューブやカテーテルなどの医療用具をカバー・固定したり、ガーゼのような多孔質体のうえから、カバー・固定する場合などが挙げられる。
かかる使用方法により、粘着性抗菌シートの面から揮散性抗菌剤を揮散させ、該粘着性抗菌シートの面から被着体に至るまでの空間および該空間に接する被着体の表面を抗菌することができる。
The adherent antibacterial sheet obtained as described above can be used as follows to antibacterial the adherend. An adhesive antibacterial sheet is used and pasted so that a space is provided between the antibacterial sheet and the adherend.
For example, a case where a medical device such as a silicon tube or a catheter is covered and fixed, or a porous material such as gauze is covered and fixed.
Volatile antibacterial agent is volatilized from the surface of the adhesive antibacterial sheet, and the surface from the surface of the adhesive antibacterial sheet to the adherend and the surface of the adherend in contact with the space are antibacterized by such a method of use. Can do.
以下に本発明の実施例を示し、さらに具体的に説明するが、本発明はこれらに限定されるものではなく、本発明の技術的思想を逸脱しない範囲内で種々の応用が可能である。 Examples of the present invention will be described below and will be described in more detail. However, the present invention is not limited to these examples, and various applications are possible without departing from the technical idea of the present invention.
ヒノキチオールのシクロデキストリン包接体含有粘着性抗菌シートの作製
＜粘着剤層の作製＞
アクリル酸イソノニル６５重量部、アクリル酸２−メトキシエチル３０重量部、アクリル酸５重量部からなる単量体混合物を、トルエン８０重量部に均一に溶解重合し、重合開始剤としてアゾビスイソブチロニトリル０．３重量部を添加して共重合反応を行い、アクリル共重合体を得た。得られたアクリル共重合体１００重量部に対して、カプリル酸トリグリセリル６０重量部、架橋剤として三官能性イソシアネート化合物（商品名：コロネートＨＬ、日本ポリウレタン社製）０．１重量部をトルエン中にて配合して均一な粘着剤溶液Ａを作製した。
Preparation of adhesive antibacterial sheet containing cyclodextrin clathrate of hinokitiol <Preparation of adhesive layer>
A monomer mixture consisting of 65 parts by weight of isononyl acrylate, 30 parts by weight of 2-methoxyethyl acrylate, and 5 parts by weight of acrylic acid is uniformly dissolved and polymerized in 80 parts by weight of toluene, and azobisisobutyro is used as a polymerization initiator. A copolymer reaction was carried out by adding 0.3 parts by weight of nitrile to obtain an acrylic copolymer. To 100 parts by weight of the obtained acrylic copolymer, 60 parts by weight of triglyceryl caprylate and 0.1 part by weight of trifunctional isocyanate compound (trade name: Coronate HL, manufactured by Nippon Polyurethane) as a crosslinking agent in toluene To prepare a uniform pressure-sensitive adhesive solution A.
一方で抗菌剤（ヒノキチオール(R)シクロデキストリン包接体：セイワテクニクス社製）７．０重量部の２０％酢酸エチル懸濁液を超音波照射で均一分散させたものを、上記粘着剤溶液Ａに滴下し、粘着剤層を作製した。 On the other hand, an antibacterial agent (hinokitiol (R) cyclodextrin inclusion body: manufactured by Seiwa Technics) 7.0 parts by weight of 20% ethyl acetate suspension uniformly dispersed by ultrasonic irradiation was used as the adhesive solution A Was added dropwise to prepare an adhesive layer.
＜粘着性抗菌シートの作製＞
上記のように作製した粘着剤層をポリウレタン／一軸延伸ポリプロピレン積層フィルムのポリウレタン側に圧着転写して貼り合わせ、本発明の方法に使用する粘着性抗菌シート（表１に記載の大きさ）を作製し、試験サンプルとした。紫外線吸収剤として酸化チタンを含み、茶色着色させた透明性のあるポリエステル／ポリエチレン積層構造の包装材料にて、粘着性抗菌シートを密封包装し、２５ｋＧｙのγ線を照射して滅菌を施した。
<Preparation of adhesive antibacterial sheet>
The pressure-sensitive adhesive layer produced as described above is pressure-transferred and bonded to the polyurethane side of the polyurethane / uniaxially stretched polypropylene laminated film to produce a pressure-sensitive adhesive antibacterial sheet (size shown in Table 1) used in the method of the present invention. And used as a test sample. The adhesive antibacterial sheet was hermetically packaged in a transparent polyester / polyethylene laminated packaging material containing titanium oxide as a UV absorber and colored brown, and sterilized by irradiation with 25 kGy of γ-rays.
ヒノキチオールＣＤ包接体：ヒノキチオール導入率１２．０ｗｔ％
ＣＤ体：０．２５ｗｔ％粘着シートの場合、ＣＤ包接体３．５重量部
ＣＤ体：０．０５ｗｔ％粘着シートの場合、ＣＤ包接体０．７重量部
フリー体：０．５０ｗｔ％粘着シートの場合、フリー体０．８重量部の１０％メタノール溶液を添加する。
Hinokitiol CD inclusion body: Hinokitiol introduction rate 12.0 wt%
CD body: In the case of 0.25 wt% adhesive sheet, CD inclusion body 3.5 parts by weight CD body: In the case of 0.05 wt% adhesive sheet, CD inclusion body 0.7 part by weight Free body: 0.50 wt% adhesion In the case of a sheet, 0.8% by weight of a 10% methanol solution of free body is added.
支持体：透湿性の高い／低い部分を設けたＰＵ
透湿性高い部分：赤（ＰＵのみ）
透湿性低い部分：青（ＰＵにＰＥＴを貼り付けた）
抗菌試験の結果は、フリー体は青の部分のみ効果が認められた。
Support: PU with high / low moisture permeability
Highly breathable part: Red (PU only)
Low moisture permeability: Blue (PET is attached to PU)
As a result of the antibacterial test, the effect of only the blue part of the free body was recognized.
各実施例および比較例にて作製した粘着性抗菌シートについて、以下に示す方法で試験を行い、その結果を表１および図に示した。 The adhesive antibacterial sheet produced in each Example and Comparative Example was tested by the method shown below, and the results are shown in Table 1 and FIG.
（実験例１）抗菌性試験
黄色ブドウ球菌(Staphylococcus aureus)またはＭＲＳＡを菌種に用いた。各菌種を、ＳＣＤ寒天培地（トリプトソーヤ寒天培地）に移植して、３７℃で２４時間培養した。発育した菌を内径１ｍｍの白金耳で１０白金耳量掻き取り滅菌生理食塩水に懸濁させた後、これを希釈して１０５ｃｆｕ／ｃｍ２の量の菌を、直径９ｃｍのシャーレ内のＳＣＤ寒天培地上に播種した。
次いで、図２に示すように、シャーレの蓋にあたる部分に表１に示す支持体形状の試験サンプルを、粘着剤層面と菌面が平行になるように設置した。なお、実施例１１、１２に用いた試験サンプルは、図３に示す形状のものを用いた。蓋をした後、３７℃で４８時間培養を行い、培養終了後の阻止円の形状と大きさを測定し、抗菌活性を調べた。その結果を表１および図４に示した。
(Experimental example 1) Antibacterial property test Staphylococcus aureus or MRSA was used for the bacterial species. Each bacterial species was transferred to an SCD agar medium (tryptosa agar medium) and cultured at 37 ° C. for 24 hours. The grown bacteria were scraped with a platinum loop having an inner diameter of 1 mm and suspended in sterilized physiological saline. The diluted bacteria were diluted with 10 5 cfu / cm 2 in a petri dish having a diameter of 9 cm. Seeded on SCD agar medium.
Next, as shown in FIG. 2, a test sample having a support shape shown in Table 1 was placed on the portion corresponding to the lid of the petri dish so that the adhesive layer surface and the bacteria surface were parallel. Note that the test samples used in Examples 11 and 12 had the shapes shown in FIG. After capping, cultivation was carried out at 37 ° C. for 48 hours, and the shape and size of the inhibition circle after completion of the cultivation were measured to examine antibacterial activity. The results are shown in Table 1 and FIG.
本発明の抗菌方法によると、粘着性抗菌シートの面から被着体に至るまでの空間および該空間に接する被着体の表面が効果的に抗菌される。例えば輸液製剤の注入時における注射針の固定や、カテーテル挿入時の固定など医療用具の固定に粘着性抗菌シートを使用する場合、該抗菌シートの面から皮膚までの空間ならびに皮膚面、特に注射針等の皮膚内部への挿入局所が効果的に抗菌される。これにより、粘着性抗菌シートと皮膚の間に空間が生じる場合であっても、外部から菌が侵入することがなく、院内感染などの菌感染を防ぐことができる。特に、支持体に紫外線吸収剤を添加したり、着色したりして、揮散性抗菌剤の光に対する安定性を向上させることにより、より効果的に抗菌効果を持続させることができる。 According to the antibacterial method of the present invention, the space from the surface of the adhesive antibacterial sheet to the adherend and the surface of the adherend in contact with the space are effectively antibacterial. For example, when an adhesive antibacterial sheet is used for fixing a medical device such as fixing an injection needle at the time of injection of an infusion preparation or a catheter, the space from the surface of the antibacterial sheet to the skin and the skin surface, particularly the injection needle Such as the insertion site into the skin is effectively antibacterial. Thereby, even if it is a case where a space arises between an adhesive antibacterial sheet and skin, bacteria do not penetrate | invade from the outside and bacteria infections, such as nosocomial infection, can be prevented. In particular, the antibacterial effect can be sustained more effectively by adding a UV absorber to the support or coloring it to improve the stability of the volatile antibacterial agent to light.
１ シャーレ
２ ゴム
３ 支持体
４ 粘着剤層
５ 培地
６ 透湿性の高い部分
７ 透湿性の低い部分
DESCRIPTION OF SYMBOLS 1 Petri dish 2 Rubber | gum 3 Support body 4 Adhesive layer 5 Medium 6 Part with high moisture permeability 7 Part with low moisture permeability
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005258070A JP2007068723A (en) | 2005-09-06 | 2005-09-06 | Antibacterial method using adhesive antibacterial sheet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005258070A JP2007068723A (en) | 2005-09-06 | 2005-09-06 | Antibacterial method using adhesive antibacterial sheet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007068723A true JP2007068723A (en) | 2007-03-22 |
Family
ID=37930706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005258070A Pending JP2007068723A (en) | 2005-09-06 | 2005-09-06 | Antibacterial method using adhesive antibacterial sheet |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007068723A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009041122A1 (en) * | 2007-09-28 | 2009-04-02 | Nichiban Co., Ltd. | Patch material |
| EP2165845A1 (en) | 2008-09-16 | 2010-03-24 | Ricoh Co., Ltd. | Thermosensitive recording medium with antibacterial property |
| EP2366554A2 (en) | 2010-03-16 | 2011-09-21 | Ricoh Company, Ltd. | Thermosensitive recording medium |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0984869A (en) * | 1995-09-25 | 1997-03-31 | Lion Corp | Plastering agent |
| JP2005120008A (en) * | 2003-10-16 | 2005-05-12 | Nitto Denko Corp | Adhesive antimicrobial sheet and antimicrobial method using the same |
-
2005
- 2005-09-06 JP JP2005258070A patent/JP2007068723A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0984869A (en) * | 1995-09-25 | 1997-03-31 | Lion Corp | Plastering agent |
| JP2005120008A (en) * | 2003-10-16 | 2005-05-12 | Nitto Denko Corp | Adhesive antimicrobial sheet and antimicrobial method using the same |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009041122A1 (en) * | 2007-09-28 | 2009-04-02 | Nichiban Co., Ltd. | Patch material |
| JPWO2009041122A1 (en) * | 2007-09-28 | 2011-01-20 | ニチバン株式会社 | Adhesive material |
| JP4755284B2 (en) * | 2007-09-28 | 2011-08-24 | ニチバン株式会社 | Adhesive material |
| KR101463644B1 (en) * | 2007-09-28 | 2014-11-19 | 니찌방 가부시기가이샤 | Patch material |
| EP2165845A1 (en) | 2008-09-16 | 2010-03-24 | Ricoh Co., Ltd. | Thermosensitive recording medium with antibacterial property |
| US8367581B2 (en) | 2008-09-16 | 2013-02-05 | Ricoh Company, Ltd. | Thermosensitive recording medium with antibacterial property |
| EP2366554A2 (en) | 2010-03-16 | 2011-09-21 | Ricoh Company, Ltd. | Thermosensitive recording medium |
| US8709974B2 (en) | 2010-03-16 | 2014-04-29 | Ricoh Company, Ltd. | Thermosensitive recording medium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4476593B2 (en) | Medical adhesive antibacterial sheet | |
| US4323557A (en) | Pressure-sensitive adhesive containing iodine | |
| US20180338945A1 (en) | Skin adhesives, antimicrobial compositions, articles, and methods for the use thereof | |
| JP6433436B2 (en) | Antibacterial adhesive with improved properties | |
| CA2802884C (en) | Antimicrobial silicone-based wound dressings | |
| ES2815660T3 (en) | Procedure for local reduction of cutaneous microbial flora | |
| CN105163768B (en) | Antimicrobial aquogel polymer | |
| JP6290184B2 (en) | Wound dressing | |
| KR20120077821A (en) | Matrix type antimicrobial vehicle and manufacturing method thereof | |
| JP2007068723A (en) | Antibacterial method using adhesive antibacterial sheet | |
| ES2372296T3 (en) | FORMULATION OF CYANOACRYLATE MONOMER CONTAINING DIYODOMETIL-P-TOLISULFONA AND HYDROXIDIFENIL ETER. | |
| KR100740596B1 (en) | A hydrogel dressing of adhesive band type and its preparation method | |
| JP2005154602A (en) | Antibacterial pressure-sensitive adhesive product | |
| JP2005304756A (en) | Skin-stickable adhesive sheet | |
| EP1689338B1 (en) | Antimicrobial adhesive system | |
| JP2014193818A (en) | Medical adhesive product | |
| WO2016135038A1 (en) | Wound dressing | |
| KR101258046B1 (en) | Matrix type antimicrobial vehicle and manufacturing method thereof | |
| JP2002315775A (en) | Pressure-sensitive adhesive sheet applied to skin | |
| JP5627936B2 (en) | Antibacterial adhesive products | |
| JP2004524291A (en) | Sterilization method of cyanoacrylate composition | |
| JPH11169452A (en) | Wound treatment material | |
| AU2012200831A1 (en) | Antimicrobial adhesive system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110309 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110704 |